Santen Pharmaceutical Co Ltd - Company Profile
Powered by 
All the data and insights you need on Santen Pharmaceutical Co Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Santen Pharmaceutical Co Ltd Strategy Report
- Understand Santen Pharmaceutical Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Santen Pharmaceutical Co Ltd (Santen) focuses on the research, development, manufacturing and marketing of pharmaceutical products and medical devices. Its product portfolio includes prescription ophthalmic products for glaucoma, bacterial conjunctivitis, dry eye, inflammation, cataract, muscae volitantes, diabetic retinopathy, retinal detachment, hyposphagma, myopia, retinal detachment, amblyopia, astigmatism, strabismus, hordeolum, VDT syndrome, and others; over-the-counter products ophthalmic products; anti-allergy ophthalmic products; and medical devices such as intraocular lenses (IOLs) and other ophthalmic products. Santen operates through its group companies located in Asia, Europe and the US. It operates production facilities in Noto, and Shiga, Japan; and Suzhou, China. Santen is headquartered in Osaka-Shi, Osaka, Japan.
Headquarters
Japan
Address
3-9-19, Shimo-Shinjo, Higashiyodogawa-Ku, Osaka-Shi, 530-8552
Website
www.santen.com
Telephone
81 6 76648621
No of Employees
4,144
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
4536 (TYO)
Revenue (2022)
$2.1B
4.8%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-154.9%
(2022 vs 2021)
Market Cap*
$3.4B
Net Profit Margin (2022)
XYZ
-152.5%
(2022 vs 2021)
* As of and is in US$
Santen Pharmaceutical Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Prescription Ophthalmic Products | Hyalein |
| Over-the-Counter Products | Eylea |
| Medical Devices | Carvit |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | New Products/Services | In April, the company and Bayer Yakuhin introduced ophthalmic VEGF inhibitor Eylea 8mg Solution for Intravitreal Injection 114.3 mg/mL. |
| 2023 | Regulatory Approval | In November, the company secured approval from the European Commission for the Marketing Authorization Application for Catiolanze (cationic emulsion of latanoprost 50μg/mL, STN1013001). |
| 2023 | Contracts/Agreements | In July, the company signed an asset transfer agreement with Harrow Health for Flarex, Natacyn, TobraDex ST, ZERVIATE, FRESHKOTE and an out-licensing agreement on the rights for product manufacturing, commercialization, and sales of Verkazia. |
Competitor Comparison
| Key Parameters | Santen Pharmaceutical Co Ltd | Astellas Pharma Inc | Daiichi Sankyo Co Ltd | Chugai Pharmaceutical Co Ltd | Hoya Corp |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Osaka-Shi | Chuo-Ku | Chuo-Ku | Chuo-Ku | Shinjuku-Ku |
| State/Province | Osaka | Tokyo | Tokyo | Tokyo | Tokyo |
| No. of Employees | 4,144 | 14,484 | 17,435 | 7,771 | 36,571 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Akira Kurokawa | Chairman | Executive Board | 2020 | - |
| Takeshi Ito | Chief Executive Officer; Director; President | Executive Board | 2022 | - |
| Kazuo Koshiji | Chief Risk Officer; Chief Financial Officer | Senior Management | 2012 | - |
| Rie Nakajima | Chief Operating Officer | Senior Management | 2023 | - |
| Nikolas Tripodis, Ph.D. | Chief Strategy Officer | Senior Management | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward